Press Releases

Umecrine Cognition presents data supporting a new predictive biomarker in patients with primary biliary cholangitis at the AASLD International Liver Meeting 2021

STOCKHOLM – Umecrine Cognition AB today announces new scientific results for its drug candidate golexanolone, linking the drug target allopregnanolone to cognitive symptoms in patients with primary biliary cholangitis. The data will be presented at The Liver Meeting Digital ExperienceTM 2021, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 12-15.

Umecrine Cognition to present at two scientific conferences on the importance of neurosteroids in cognitive dysfunction associated with liver disease

STOCKHOLM – October 6, 2021. Umecrine Cognition AB, whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE) and other CNS-related disorders, will present at two upcoming meetings pertaining to the potential benefit of golexanolone for cognitive abnormalities in patients with liver disease.

Umecrine Cognition CEO Magnus Doverskog to present at Vator Securities Healthcare Innovation Summit

STOCKHOLM. Umecrine Cognition announced today that CEO Magnus Doverskog will present at Healthcare Innovation Summit on October 7, 2021. Vator Securities Healthcare Innovation Summit is a digital investor event including some of the most innovative and fastest growing companies in the healthcare sector. The event will include focused insights into these healthcare companies, including fire side chats and panel discussions with experts within healthcare and healthcare investments.

Umecrine Cognition announces publication in the Journal of Hepatology of the results of a pilot study of golexanolone in patients with hepatic encephalopathy

STOCKHOLM. Umecrine Cognition AB today announced that the Journal of Hepatology has published safety, pharmacokinetic, and preliminary efficacy results from the pilot Phase 2a study of golexanolone in patients with cirrhosis and covert hepatic encephalopathy (HE). The clinical trial results demonstrate that the company’s candidate drug, golexanolone, improved neuropsychiatric performance at doses which are well tolerated and exhibit excellent pharmacokinetics.

Umecrine Cognition to present clinical Phase 2a results at AASLD International Liver Meeting

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company whose novel orally-active GABAA receptor modulating steroid antagonist, golexanolone, is in clinical development for hepatic encephalopathy (HE), will present clinical results from its Phase 2a study at The Liver Meeting Digital ExperienceTM 2020, the premier Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 13-16, 2020.

Umecrine Cognition announces positive additional endpoint data from a phase 2a study with golexanolone in hepatic encephalopathy

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced positive data based on prespecified analyses of additional endpoint data from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in patients with cirrhosis and evidence of mild cognitive impairment consistent with hepatic encephalopathy.

Umecrine Cognition announces top-line results from its phase 2a study with golexanolone in hepatic encephalopathy

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company focused on developing a new class of neurosteroid based drugs for CNS disorders, today announced results based on initial review of the topline data set from a phase 2a study of the safety, pharmacokinetics and exploratory efficacy of golexanolone (formerly GR3027) in hepatic encephalopathy.

Umecrine Cognition announces a Notice of Allowance from USPTO for a patent protecting a pharmaceutical formulation of its proprietary lead compound golexanolone

STOCKHOLM. Umecrine Cognition AB, a Karolinska Development (NASDAQ Stockholm: KDEV) portfolio company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent protecting a pharmaceutical formulation of its lead candidate drug golexanolone, currently in clinical Phase 2a development for hepatic encephalopathy. Upon issuance, the granted patent will expire in 2038.